<H1>INTRODUCTION
Cancer affecting the urinary bladder is a prevailing disease worldwide, with epidemiological studies reporting its incidence at 541,000 cases per year globally, and approximately 150,000 deaths per year [1] . The most common histological types of bladder cancer -urothelial carcinoma (UC) and its ten different variants recognized by WHO [2] , squamous cell carcinomas, adenocarcinomas, and undifferentiated carcinomas [2] have been extensively described. In contrast, clear cell urothelial carcinoma (CCUC) of the urinary bladder is a rare neoplasm; to our knowledge, with only 13 cases reported in the literature [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] , including our case at the time of this review.
<H1>CASE REPORT
An 81-year-old male presented to our hospital with gross hematuria and acute urinary retention.
Computed tomography (CT) scan revealed an 7.5/7/4 cm exophytic mass arising on the posterosuperior aspect of the urinary bladder, extending beyond the bladder wall, infiltrating the perivesical fat with no evidence of metastasis. Transurethral resection of the urinary bladder tumor (TURBT) was performed, a diagnosis of CCUC was established, and a radical cystoprostatectomy was decided.
The gross examination of the resection specimen revealed a large and hemorrhagic exophytic urinary bladder mass involving the posterior wall and extending to the dome of the bladder, (Table 1) . Based on histological features and IHC profile, the diagnosis of urothelial carcinoma with clear cell differentiation was established. Shortly after, the patient developed bone metastases, and he died 5 months after the diagnosis.
<H1>DISCUSSION
The CCUC affecting the urinary bladder is a rather new and sporadic diagnosis encountered in the pathology of urinary tract tumors. Limited reports have been made since 1995 when it was first described by Kotliar et al. [3] as a recognizable variant of urothelial carcinoma. Frequently, clear cell components are encountered in UC; however, Knez et al. [11] were the first to use a cut-off percentage (~90%) of clear cells to differentiate CCUC. Due to the limited knowledge regarding CCUC, as a pathologic entity and its prognosis, the true incidence of CCUC is uncertain. However, a three-fold increase in published cases is observed starting from 2010. This can be due to an increase in IHC use, more reliable antibodies, better scientific communication, and a better understanding of the pathology of bladder tumors.
Based on the 13 reported cases in the literature, including our case, a clear predisposition toward male sex is found (male:female -12:1), with a mean age at diagnosis of 71.5 years (range, 55-82) [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . At initial presentation, gross hematuria is the most frequently encountered symptom (10 cases) [3, 5, 6, 8, [10] [11] [12] [13] . Among the 13 documented cases, tumor extension was provided for 9 cases [3-5,7,9-11,13] while for 3 cases no data was available [6, 8, 12] ; thereafter 4 cases were pT2, 5 cases pT3, and 1 case was pT4. Only 7 cases had undergone radical removal of the urinary bladder [3, 4, 7, 9, 11, 13] . Of the 13 cases, 3 patients died (with a mean survival of 9.5 months) [3, 9] , 8 patients were alive at follow-up (with a mean follow-up period of 16 months), and 2 cases had no follow-up data available (Table 2 ).
Clear cell carcinomas may occur in almost any site, making the differential diagnosis problematic. Taking into consideration that the clear cell tumor was located in the urinary bladder, our first differential diagnosis was with clear cell adenocarcinoma of the urinary bladder.
In our case, the tumor presented a solid, sheet-like growth pattern ( Figure 2A ) and was PAX8 negative. In contrast, clear cell adenocarcinoma is PAX8 positive [11, [14] [15] [16] , and it can have a solid growth pattern with glandular differentiation and tubulocystic or papillary morphology, with or without hobnail cells [2, 16] . Based on the negative reaction of the tumor cells for RCC, HMB-45/S-100, PSA, PLAP, and vimentin, secondary involvement of the urinary bladder by clear cell carcinoma of the kidney, melanoma, prostate cancer, seminoma, or by clear cell sarcoma was excluded. Aspects which were confirmed by whole-body CT -scan results.
Moreover, the presence of high-grade urothelial carcinoma and CIS favored the diagnosis of a primary tumor.
The tumor cells were focally positive for PAS (Figure 2B ), confirming the presence of cytoplasmic polysaccharides, such as glycogen, and not mucin or lipids. Regarding this aspect, Kotliar et al. [3] suggested that the loss or the focal positivity for PAS/PAS-D could be correlated with the tumor grade, more precisely with a poorly differentiated, aggressive tumor, a feature that was noticed in our case as well.
Mai et al. [13] observed that the expression of basal cell markers CK5 and CD44 in CCUC, indicating a basal-like phenotype of the tumor cells, is consistent with an aggressive behavior.
Based on these criteria, our patient fitted the expected outcome, with aggressive and rapid clinical evolution of the disease and the development of bone metastases, followed by death 5 months after the initial diagnosis was established.
<H1>CONCLUSION
In conclusion, CCUC is a rare variant of UC; to our knowledge, the present case is the first reported case in Romania. The differential diagnosis with more common malignant primary tumors, as well as metastatic lesions, should be made based on the correlation of histological aspects and histochemical and IHC staining. CCUC has a higher incidence in the elderly (eighth decade of life), typically affects male patients, requires an aggressive treatment, and has a variable outcome.
To properly characterize CCUC as a pathological entity, we need to study in detail more cases.
Moreover, tumor behavior needs to be defined, and a uniform therapeutic guideline must be established.
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